Founded in 2001 by Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in ophthalmology, optometry, orthopedics and wound care. The Company has pioneered stem cell research using human amniotic membrane to treat corneal surface conditions and developed Amniograft™, the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation. The National Institute of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, 130,000 human implants have been conducted using the Company’s patented Crotek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology platform.

Industry Sectors

Headquarters

Doral, FL; Atlanta, GA

Investment Status

active

Recent Company News

TissueTech recruits Arnott for board

Aug 04, 2017
TissueTech Inc. announced today that it has named John Arnott to its board of directors. Mr. Arnott was most recently Operating Partner and Executive Chairman o...
Read More